ClinicalTrials.gg
Active, not recruitingNCT05865496Updated Jan 12, 2024

A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps

A Phase 2 interventional study of 611 and Placebo in Sinusitis, Nasal Polyps and Polyps, sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Active, not recruiting at 4 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (part of 3SBio Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Sinusitis with a site in China — 5 open to participants now, 7 under way, 1 of them phase 3. Sinusitis · China.

Planned enrollment
5th of 12
90 · median 79
Started
2023
with 2 others
Phase 2
4 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
2 of 14
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Among the 14 studies in Sinusitis with a site in China, this one is the 5th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 7th registered.

Sinusitis

256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.

Browse Sinusitis studies →

Open to participants now

5 of the 14 studies in Sinusitis with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 15 Sinusitis studies recruiting now, 6 (40%) set no upper age limit and 6 (40%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Sinusitis with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).

Read the detailed description

The main purpose is to evaluate the effect of 611 on a background of mometasone furoate nasal spray (MFNS) in reducing endoscopic nasal polyp score (NPS) and nasal congestion/obstruction score (NCS) severity in eligible patients with CRSwNP whose disease remains inadequately controlled despite daily treatment with intranasal corticosteroid (INCS) therapy in comparison to placebo.

03

Conditions studied

  • Sinusitis
  • Nasal Polyps
  • Polyps
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female and male patients aged ≥18 and ≤ 75 years at the time of screening.
  2. Bilateral CRSwNP.
  3. Bilateral NPS of ≥5 with a minimum score of 2 in each nasal cavity
  4. Nasal Congestion Score of > 2 at screening and a weekly average severity of > 1 at time of randomization.
  5. Patients whose bilateral sino-nasal polyposis remains inadequately controlled despite prior treatment with SCS anytime within the past 2 years; and/or had a medical /intolerance to SCS; and/or received nasal polyp surgery 6 months before signing the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Patients with other nasal diseases or symptoms.
  2. Patients who are taking or have taken the following prohibited therapies as specified, e.g., systemic within 4 weeks prior to screening, less than 3 months or 5 half-lives for biologic therapy prior to screening.
  3. Patients who have active , or infections as determined by positive results at Screening.
  4. History of cancer.
  5. Known or suspected history of .
  6. Known with allergic or intolerant to mometasone furoate spray or 611/placebo.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    611 Dose A

    611 300 mg Q2W, subcutaneous (SC) injection.

    Drug: 611

  • Experimental
    611 Dose B

    611 450 mg Q4W, subcutaneous (SC) injection.

    Drug: 611

  • Placebo comparator
    Placebo

    Placebo subcutaneous (SC) injection.

    Drug: Placebo

Interventions

  • Drug611

    611 subcutaneous (SC) injection.

  • DrugPlacebo

    Placebo subcutaneous (SC) injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 16 in Bilateral Nasal Polyp Score (NPS)

    NPS is evaluated by nasal endoscopy. For each nostril, NPS is graded based on polyp size from 0 = no polyps to 4 = large polyps causing complete obstruction of inferior nasal cavity; lower score = smaller sized polyps. Bilateral NPS is the sum of right and left nostril scores, ranges from 0 (no polyps) to 8 (large polyps), higher score = more severe disease.

    Time frame: Up to 16 weeks

  2. Change From Baseline at Week 16 in Nasal Congestion Symptom Severity Score (NCS)

    NCS is assessed by the participants daily from visit 1 and throughout the study on a scale of 0 to 3, where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms, with higher scores indicates more severity.

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Change From Baseline to the End of study in Lund Mackay Score

    The Lund Mackay Score scoring system rates each of both the left and right frontal, maxillary, sphenoid, ostiomeatal complex, anterior ethmoid and posterior ethmoid sinuses using following grading: 0 = normal, 1 = partial opacification, 2 = total opacification. The total score is the sum of scores from each side and ranges from 0 (normal) to 24 (more opacified); higher score indicated more severe disease.

    Time frame: Up to 16 weeks

  2. Change From Baseline to the End of study in Total Nasal Symptom Score (TNSS)

    TNSS is a composite of nasal congestion, loss of smell, and rhinorrhea (anterior/posterior nasal discharge), each access on 0-3 categorical scale (where 0 = no symptoms, 1 = mild symptoms, 2 = moderate symptoms and 3 = severe symptoms). Total score ranges from 0 (no symptoms) to 12 (severe symptoms). Higher score indicated more severe symptoms.

    Time frame: Up to 16 weeks

  3. Change From Baseline to the End of study in the University of Pennsylvania Smell Identification Test (UPSIT) Score

    The UPSIT is a 40-item test to measure the individual's ability to detect odors. Total score ranges from 0 (anosmia) to 40 (normal sense of smell), lower score indicated severe smell loss.

    Time frame: Up to 16 weeks

  4. Change From Baseline to the End of study in 22-item Sino-nasal Outcome Test (SNOT-22) Scores

    The SNOT-22 is a validated questionnaire that used to assess the impact of chronic rhinosinusitis phenotype with nasal polyps (CRSwNP) on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life.

    Time frame: Up to 16 weeks

  5. 611 Concentration in Serum

    The concentration of 611 in Serum.

    Time frame: Up to 24 weeks

07

Study locations

4 sites
  • Site 03
    Beijing, Beijing 100005, China
  • Site 01
    Beijing, Beijing 100730, China
  • Site 04
    Wuhan, Hubei 430022, China
  • Site 02
    Xuzhou, Jiangsu 221004, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for May 2024, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
May 19, 2023
StartActual
Jun 30, 2023
Primary completionEst.
May 31, 2024
CompletionEst.
Jul 31, 2024
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05865496
Responsible party
Sponsor
First posted
May 19, 2023
Start date
Jun 30, 2023
Primary completion
May 31, 2024 (estimated)
Completion
Jul 31, 2024 (estimated)
Last update
Jan 12, 2024

Study contacts

Qinghong Zhou, BS
study director · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Luo Zhang, MD
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Camtarkibart

Start the discussion